Fresh analysis suggests that individuals who stop using new slimming jabs like Mounjaro or Wegovy may regain reduced body mass far faster than those who end traditional lifestyle plans.
Published data in a prominent health publication demonstrates that while obese individuals can lose a large proportion of their body weight while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"People purchasing such treatments must be cognizant of the potential of rapid weight regain when the medication concludes," cautioned expert Dr. Susan Jebb.
That rate of regain means a reversion to starting weight within about 18 months.
Analyzing Therapies
The analysis, which looked at dozens of studies involving thousands of patients, contrasted the effects of these new drugs with older methods.
The team emphasize that individuals who shed pounds through lifestyle changes alone typically see a more gradual creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors propose the mode of action of the drugs accounts for the amplified weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication leads to hunger is uncontrolled, making binge eating far more likely."
A Chronic Condition?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, due to the significant potential of weight regain, the treatment should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who note that the results "highlight the persistent character of excess weight," akin to managing diseases like high blood pressure.
Patient Experiences
Individuals who have stopped the jabs report a powerful resurgence of hunger.
"I experienced something flipping and you become starving," recalled an individual.
This difficulty is worsened if individuals have not adopted lasting dietary or behavioural changes during treatment.
Widespread Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a permanent cure and long-term success hinges on combined lifestyle management.
